Literature DB >> 29527657

Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies.

Chiara Vendramin1, Mari Thomas2, John-Paul Westwood1, Siobhan McGuckin1, Marie Scully2.   

Abstract

Entities:  

Keywords:  adverse drug reaction; antibodies to rituximab; rituximab: serum sickness; thrombotic thrombocytopenic purpura

Mesh：

Substances：

Year:  2018        PMID： 29527657     DOI： 10.1111/bjh.15177

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.

Authors:  Manuel Alfredo Podestà; Barbara Ruggiero; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  BMJ Case Rep       Date:  2020-01-23

Review 2.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

Review 3.  Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase.

Authors:  John Paul Westwood; Marie Scully
Journal:  Ther Adv Hematol       Date:  2022-07-26

4.  Anti-CD20 therapeutic options in immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Robert W Maitta
Journal:  Br J Haematol       Date:  2022-04-26       Impact factor: 8.615

5.  Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.

Authors:  Quentin Bertrand; Sabine Mignot; Theresa Kwon; Anne Couderc; Anne Maisin; Alexandra Cambier; Véronique Baudouin; Marine Peyneau; Georges Deschênes; Julien Hogan; Claire Dossier
Journal:  Pediatr Nephrol       Date:  2021-06-16       Impact factor: 3.714

Review 6.  Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

Authors:  Serena Brancati; Lucia Gozzo; Laura Longo; Daniela Cristina Vitale; Filippo Drago
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.